Info

ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company’s lead products, which are in clinical-stage testing, consist of ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase; ARQ 501, an intravenously administered activator of the cell's deoxyribonucleic acid (DNA) damage response mechanism mediated by the E2F-1 transcription factor, and ARQ 171, an intravenously administered second-generation activator of E2F-1. Early-stage clinical trial results, which are available for ARQ 197 and ARQ 501, have demonstrated anti-cancer activity across various types of tumors.(Source: 10-K)